Trade Catalyst Pharmaceuticals - CPRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 14.64 |
| Open | 14.7 |
| 1-Year Change | -8.3% |
| Day's Range | 14.7 - 14.96 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 14.64 | -0.19 | -1.28% | 14.83 | 14.94 | 14.54 |
| Apr 24, 2024 | 15.08 | 0.30 | 2.03% | 14.78 | 15.14 | 14.69 |
| Apr 23, 2024 | 14.69 | -0.43 | -2.84% | 15.12 | 15.17 | 14.69 |
| Apr 22, 2024 | 15.07 | -0.14 | -0.92% | 15.21 | 15.25 | 14.89 |
| Apr 19, 2024 | 15.07 | -0.16 | -1.05% | 15.23 | 15.76 | 14.99 |
| Apr 18, 2024 | 15.30 | -0.67 | -4.20% | 15.97 | 16.18 | 15.29 |
| Apr 17, 2024 | 15.95 | 0.32 | 2.05% | 15.63 | 16.01 | 15.59 |
| Apr 16, 2024 | 15.48 | 0.28 | 1.84% | 15.20 | 15.65 | 15.12 |
| Apr 15, 2024 | 15.36 | -0.05 | -0.32% | 15.41 | 15.78 | 15.22 |
| Apr 12, 2024 | 15.18 | -0.62 | -3.92% | 15.80 | 15.82 | 15.05 |
| Apr 11, 2024 | 15.77 | -0.09 | -0.57% | 15.86 | 15.92 | 15.52 |
| Apr 10, 2024 | 15.83 | 0.46 | 2.99% | 15.37 | 15.92 | 15.20 |
| Apr 9, 2024 | 15.76 | 0.25 | 1.61% | 15.51 | 15.77 | 15.37 |
| Apr 8, 2024 | 15.46 | 0.20 | 1.31% | 15.26 | 15.87 | 15.13 |
| Apr 5, 2024 | 15.13 | 0.21 | 1.41% | 14.92 | 15.29 | 14.92 |
| Apr 4, 2024 | 15.07 | -0.46 | -2.96% | 15.53 | 15.57 | 15.02 |
| Apr 3, 2024 | 15.44 | 0.30 | 1.98% | 15.14 | 15.45 | 15.03 |
| Apr 2, 2024 | 15.20 | -0.21 | -1.36% | 15.41 | 15.41 | 15.10 |
| Apr 1, 2024 | 15.69 | -0.05 | -0.32% | 15.74 | 15.88 | 15.29 |
| Mar 28, 2024 | 15.88 | -0.36 | -2.22% | 16.24 | 16.40 | 15.73 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Pharmaceuticals Company profile
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Catalyst Pharmaceuticals Inc revenues increased 18% to $140.8M. Net income decreased 47% to $39.5M. Revenues reflect Revenues increase of 16% to $138M. Net income was offset by Selling, general and adminis - Balancing increase of 14% to $45.2M (expense), reasear increase of 3% to $15.3M (expense), Other income, net decrease of 52% to $282K (income).
Equity composition
Common Stock $.001 Par, 4/11, 100M auth., 21,654,680 issd. Insiders own 22.54%. IPO 8/11/06, 3,350,000 shares @ $6 per share by First Albany Capital Inc. and Stifel, Nicolaus & Company, Incorporated. 9/08, P.O of 1.5M shares.
| Industry: | Biopharmaceuticals |
355 Alhambra Circle
Suite 801
CORAL GABLES
FLORIDA 33134
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com